Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

Statins and Diabetes: Causal Link Reinforced in New Analysis

News Daily News

Statins and Diabetes: Causal Link Reinforced in New Analysis

Michael O'Riordan

October 25, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

News Conference News ESC 2017

CHANGE DAPT: Study Contests Benefit of Ticagrelor Over Clopidogrel After PCI in ACS

August 30, 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Evolocumab Not Cost-Effective at Current List Price

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Industry News

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

August 15, 2017

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

July 24, 2017

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.